Management of Resistant Trichomoniasis

  • Cynthia Alessio
  • Paul NyirjesyEmail author
Female Genital Tract Infections (J Sobel, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Female Genital Tract Infections


Purpose of Review

Trichomonas vaginalis is the most prevalent sexually transmitted parasite in the USA; resistant infection is emerging. New drug therapies and dosing regimens of standard therapies are being studied to treat resistant infection.

Recent Findings

Diagnosis of trichomoniasis has become more sensitive, specific, and widely available with the advent of nucleic acid amplification tests (NAATs). Women with resistant trichomoniasis should be treated with high-dose regimens of metronidazole or tinidazole. Alternative treatment options have been described, and there has been some success particularly with high-dose tinidazole/intravaginal paromomycin cream combination, intravaginal boric acid, and intravaginal metronidazole/miconazole.


Resistant trichomoniasis is a growing public health concern with implications for long-term health consequences. More data are needed to further evaluate mechanisms by which resistance occurs as well as promising therapies for those affected.


Trichomonas vaginalis Trichomoniasis Metronidazole Tinidazole Resistant trichomoniasis Metronidazole resistance 


Compliance with Ethical Standards

Conflict of Interest

Dr. Alessio has no conflicts of interest to disclose.

Dr. Nyirjesy has received grants from Mycovia Pharmaceuticals; Curatek Pharmaceuticals; Scynexis, Inc.; and Hologic. He also serves as a consultant for Mycovia Pharmaceuticals; Lupin Pharmaceuticals; Hologic; Scynexis, Inc.; Daré Bioscience; Inc.; and BD.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR, et al. A review of evidence-based care of symptomatic trichomoniasis and asymptomatic Trichomonas vaginalis infections. Clin Infect Dis. 2015;61(Suppl 8):S837–48. Scholar
  2. 2.
    Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307. Scholar
  3. 3.
    Seña AC, Bachmann LH, Hobbs MM, et al. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther. 2014;12(6):637–685. Scholar
  4. 4.
    Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001e2004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36:738e44.CrossRefGoogle Scholar
  5. 5.
    Byun JM, Jeong DH, Kim YN, et al. Experience of successful treatment of patients with metronidazole-resistant Trichomonas vaginalis with zinc sulfate: a case series. Taiwan J Obstet Gynecol. 2015;54(5):617–20. Scholar
  6. 6.
    Miller MR, Nyirjesy P. Refractory trichomoniasis in HIV-positive and HIV-negative subjects. Curr Infect Dis Rep. 2011;13(6):595–603. Scholar
  7. 7.
    Lobo T, Feijo G, Carvalho S, Costa P, Chagas C, Xavier J, et al. A comparative evaluation of the Papanicolaou test for the diagnosis of trichomoniasis. Sex Transm Dis. 2003;30(9):694–9. Scholar
  8. 8.
    Nyirjesy, P. Trichomoniasis and the 2015 CDC STD treatment guidelines: new insights, new urgency. OBG Manag 2016:S4–S6.Google Scholar
  9. 9.
    Lossick JG. The diagnosis of vaginal trichomoniasis. JAMA. 1988;259(8):1230. Scholar
  10. 10.
    Van Der Pol B, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol. 2006;44:366–73.CrossRefGoogle Scholar
  11. 11.
    Hillier SL, Danby C The end of the wet mount. OBG Manag 2016: S2–S4.Google Scholar
  12. 12.
    Schwebke JR, Gaydoes CA, Davis T, et al. Clinical evaluation of the Cepheid Xpert TV assay for detection of Trichomonas vaginalis with prospectively collected specimens from men and women. J Clin Microbiol. 2018;56(2):e01091–17. Scholar
  13. 13.
    Van Der Pol B, Williams JA, Fuller D, et al. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. J Clin Microbiol. 2017;55(1):155–64.CrossRefGoogle Scholar
  14. 14.
    Kawa D, Kostiha B, Yu JH, et al. Elevating the standard of care for STIs: the BD Max CT/GC/TV assay. 2017.Google Scholar
  15. 15.
    Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sex Transm Dis Guidel. 2015;64(RR-03):1–137.Google Scholar
  16. 16.
    Cartwright CP, Lembke BD, Ramachandran K, Body BA, Nye MB, Rivers CA, et al. Comparison of nucleic-acid amplification assays with BD affirm VPIII for the diagnosis of vaginitis/vaginosis in symptomatic women. J Clin Microbiol. 2013;51(11):3694–9. Scholar
  17. 17.
    •• Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis. 2017;44(1):29–34. Study shows single dose has a higher failure rate than multidose regimen.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother. 2003;47:1407–9.CrossRefGoogle Scholar
  19. 19.
    Craig-Kuhn MC, Granade C, Muzny C, et al. Optimal timing for Trichomonas vaginalis test of cure using nucleic acid amplification testing. Sex Transm Dis. 2019;46:312–6.CrossRefGoogle Scholar
  20. 20.
    Moraes ME, Cunha GH, Bezerra MM, et al. Efficacy of the Mentha crispa in the treatment of women with Trichomonas vaginalis infection. Arch Gynecol Obstet. 2012;286:125–30.CrossRefGoogle Scholar
  21. 21.
    Ghosh AP, Aycock C, Schwebke JR. In vitro study of the susceptibility of clinical isolates of Trichomonas vaginalis to metronidazole and secnidazole. Antimicrob Agents Chemother. 2018;62(4):e02329–17.CrossRefGoogle Scholar
  22. 22.
    Bosserman EA, Helms DJ, Mosure DJ, Secor WE, Workowski KA. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis- infected women with clinical treatment failure. Sex Transm Dis. 2011;38(10):983–7.CrossRefGoogle Scholar
  23. 23.
    • Chacon MO, Fonseca THS, Oliveira MA, et al. Chlorinated metronidazole as a promising alternative for treating trichomoniasis. Parasitol Res. 2018;117(5):1333–40 In vitro study demonstrating that altering the nitro group of metronidazole may make the drug more efficacious for treating resistant strains of T. vaginalis . CrossRefGoogle Scholar
  24. 24.
    Leitsch D. Recent advances in the trichomonas vaginalis field. F1000Res. 2016;5:F1000 Faculty Rev-162. Scholar
  25. 25.
    Ertabaklar H, Yaman KS, Malatyali E, et al. Investigation of in vitro metronidazole resistance in the clinical isolates of Trichomonas vaginalis. Mikrobiyol Bul. 2016;50(4):552–8.CrossRefGoogle Scholar
  26. 26.
    Abdel-Magied AA, El-Kholya EI, Abou El-Khair SM, et al. The genetic diversity of metronidazole susceptibility in Trichomonas vaginalis clinical isolates in an Egyptian population. Parasitol Res. 2017;116(11):3125–30. Scholar
  27. 27.
    Matini M, Maghsood AH, Mohebali M, Rabiee S, Fallah M, Rezaie S, et al. In vitro susceptibility of Iranian isolates of Trichomonas vaginalis to metronidazole. Iran J Parasitol. 2016;11(1):46–51.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Waters LJ, Dave SS, Deayton JR, French PD. Recalcitrant Trichomonas vaginalis infection – a case series. Int J STD AIDS. 2005;16:505–9.CrossRefGoogle Scholar
  29. 29.
    Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis. 2001;33:1341–6.CrossRefGoogle Scholar
  30. 30.
    Hager DW. Treatment of metronidazole-resistant trichomonas vaginalis with tinidazole: case reports of three patients. Sex Transm Dis. 2004;31:343–5.CrossRefGoogle Scholar
  31. 31.
    Tayal SC, Ochogwu SA, Bunce H. Paromomycin treatment of recalcitrant Trichomonas vaginalis. Int J STD AIDS. 2010;21:217–8.CrossRefGoogle Scholar
  32. 32.
    Nyirjesy P. Paromomycin for nitroimidazole-resistant trichomonosis. Lancet. 1995;346:1110.CrossRefGoogle Scholar
  33. 33.
    Coelho DD. Metronidazole resistant trichomoniasis successfully treated with paromomycin. Genitourin Med. 1997;73:397–8.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Poppe WAJ. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol. 2001;96:119–20.CrossRefGoogle Scholar
  35. 35.
    Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis. 2011;38(10):962–3. Scholar
  36. 36.
    •• Henien M, Nyirjesy P, Smith K. Metronidazole-resistant trichomoniasis: beneficial pharmacodynamic relationship with high-dose oral tinidazole and vaginal paromomycin combination therapy. Sex Transm Dis. 2019;46(1):e1–2. Combination therapy with high-dose tinidazole and paromomycin shows promising results.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Thorley N, Ross J. Intravaginal boric acid: is it an alternative therapeutic option for vaginal trichomoniasis? Sex Transm Infect. 2018;94:574–7. Boric acid may be a good alternative therapeutic option for resistant infection.CrossRefPubMedGoogle Scholar
  38. 38.
    Helms DJ, Mosure DJ, Secor WE, et al. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol. 2008;198:370–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyDrexel University College of MedicinePhiladelphiaUSA

Personalised recommendations